Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Tech Master who wrote (14504)	6/21/1998 4:03:00 PM
From: V.	Respond to of 17305

Tech Master, I am quite disturbed that you and others continually encourage folks to add to their positions in the Y2K sector. (Please note then that this is not directed solely at you, nor is it intended as an attack.) Sure, they should be performing, and particularly in light of the recent news you posted. Yes, it's a tremendously big issue to be faced, and it is now upon us. However, the last time everyone here was saying, "Let's jump on ALYD again, 'cause it's going up up up..." it didn't. I warned that it would not. I'm no expert by a long shot, it seemed clear to me based on the market sentiment at that time. I was concerned then as I am now that cash needs to be conserved during this market volatility which involves global economic factors of great magnitude. As Kev just warned, who knows where the bottom is on some of these issues anyway? ALYD is cheap here. I doubt it will go much lower, truthfully. But, it could stay in this range for some time. Is it best to invest in a stock that might go sideways or move up and down a couple of points periodically when there are other means of producing income right now which are less risky and pay reasonably well? Like cash, for example. <gg> I worried several weeks ago that people would jump in on ALYD thinking they'd make several points (13ish to 20ish as discussed on the board). Some could've made perhaps ~4 if they had timed it perfectly in May... However, those who didn't trade it out would be flat or have lost money at this point in time. Hey, tomorrow, it could run to 17. If the market is up, there's some PR or those evil market makers manipulate the stock yet again <ggggg> ... it could kick up a few points and we could all be rich... And what if that doesn't come to pass? Are you really that comfortable with the market now to continue to suggest it's time to accumulate the Y2Ks until the bearish trend has reversed and confirmed on ALYD, let alone the overall market? techstocks.com Again, seems more prudent in these precarious financial times to jump on board of the train a bit late and make a little less profit in the end than to take one's cash reserves now and throw it blindly into more more more shares representing the idealistic hopes and dreams of tomorrow. This is just my opinion, and I don't want to argue this; it's not my intention. Nor do I disrespect your or anyone's opinion on this board. In fact, I have the highest regard for many here personally and professionally. I just get tired of the same old hype... and I worry for many who hang on every word that's written here because whether or not they should take anyone's two cents to heart... it does happen with relatively high frequency from all that I can see. For the record, I'm still long on ALYD and holding. I'm very disappointed with it, however. My purpose in commenting on this issue is therefore not to derive any personal gain, but to voice another opinion, unpopular though it might be. As always, my best to you. Regards, V.

To: Tech Master who wrote (14504)	6/24/1998 2:13:00 PM
From: Jeffrey S. Mitchell	Read Replies (2) \| Respond to of 17305

Schering-Plough Acquires Marketing Rights to Ribi's Melacine in Canada HAMILTON, Mont. and EDMONTON, Alberta, June 24 /PRNewswire/ -- Ribi ImmunoChem Research, Inc. (Nasdaq: RIBI - news) announced today that Schering-Plough Corporation (NYSE: SGP - news) of Madison, New Jersey, has acquired exclusive rights in Canada to distribute, market and sell Melacine melanoma theraccine, Ribi's novel therapeutic melanoma vaccine currently under regulatory review. This amends the distribution agreement for Melacine announced in March of 1998 and gives Schering-Plough exclusive marketing rights to Melacine on a worldwide basis, once approved. Canadian marketing rights to Melacine were previously held by Biomira Inc. (Nasdaq: BIOMF - news) of Edmonton, Alberta. ''We are very pleased to expand our agreement with Schering-Plough to include Canada,'' said Robert E. Ivy, CEO, President and Chairman of Ribi ImmunoChem Research, Inc. ''Their knowledge of the worldwide oncology market and biotherapeutic experience selling Intron A (interferon alfa-2b, recombinant) as adjuvant therapy for early-stage melanoma makes Schering-Plough Ribi's ideal partner to market Melacine as a patient-friendly therapy for the treatment of melanoma.'' Alex McPherson, MD, PhD, Biomira's President and CEO, said ''Relinquishing the Canadian marketing rights for Melacine is in line with our announced focus on our own vaccine product candidates. From a business perspective, it would not be prudent for Biomira to build the infrastructure necessary for Canadian marketing at this time. We have, however, been pleased to play a role in working with Ribi toward this pending Canadian approval and any financial obligations on Biomira's part have been recovered in this transfer agreement.'' Ribi filed a New Drug Submission (NDS) for Melacine in Canada in 1997 based on results of a completed Phase 3 clinical study in patients with Stage IV melanoma. An answer is expected in the near future. In addition to the Canadian NDS, a Marketing Authorization Application for Melacine as monotherapy for Stage IV (disseminated) melanoma was filed with the European Medicines Evaluation Agency in March of 1998, with a decision expected by the end of this year. Ribi also plans to file a Biologic License Application for Melacine with the U.S. Food and Drug Administration in the second half of 1998. If approved, Melacine potentially would be the first tumor-specific therapeutic cancer vaccine to be commercialized. When all patient data included in the completed Phase 3 trial were analyzed, no statistically significant difference in median survival was found between the Melacine arm and the commonly used four-drug chemotherapy arm. However, when data on only those patients who experienced complete and partial objective clinical responses were analyzed, there was a trend favoring Melacine, with a median survival of 34 months compared to 15 months for patients treated with chemotherapy. Further, patients receiving Melacine enjoyed superior quality of life during therapy as compared to the four-drug chemotherapy control arm. Melacine is also being studied in two additional Phase 3 trials. The Southwest Oncology Group is conducting a trial of Melacine in patients with Stage II melanoma, as adjuvant therapy after surgical removal of primary disease. In cooperation with Schering-Plough, Ribi is conducting a trial using combination therapy of Melacine and Intron A in Stage IV melanoma. Results from these two trials are expected in 1999. ''Ribi is very enthusiastic regarding the potential approval of Melacine from the Canadian, European and U.S. regulatory agencies, and the support of Schering-Plough as our marketing partner. We are working together closely to take advantage of their expertise in the regulatory review process and to coordinate Ribi's plans for producing commercial quantities of Melacine,'' explained Mr. Ivy. ''If approved for use in all stages of melanoma, worldwide sales of Melacine could approach between $300-400 million annually.'' Ribi ImmunoChem Research, Inc., a biopharmaceutical company founded in 1981, is engaged in the development of immunomodulators for use in preventing and treating human disease. Forward Looking Information Statements in this news release are based on current expectations. Actual results may differ materially based upon various risk factors. Additional information regarding risk factors is contained in the Company's Form 10-K for the year ended 1997, as filed with the U.S. Securities and Exchange Commission. SOURCE: Ribi ImmunoChem Research, Inc. ------------------------------------------------------------------------ More Quotes and News: Biomira Inc (Nasdaq:BIOMF - news)Ribi Immunochem Research Inc (Nasdaq:RIBI - news)Schering-Plough Corp (NYSE:SGP - news) Related News Categories: biotech, medical/pharmaceutical